Today: 30 June 2026
ASML stock price: Morgan Stanley’s €1,400 target sets up a tense run into earnings
19 January 2026
1 min read

ASML stock price: Morgan Stanley’s €1,400 target sets up a tense run into earnings

Amsterdam, Jan 19, 2026, 00:11 CET — The market has closed.

  • Shares of ASML in Amsterdam closed 1.6% higher, at 1,167.20 euros.
  • Morgan Stanley raised its ASML price target 40%, now at €1,400, maintaining an Overweight rating.
  • ASML will release its quarterly and full-year results on Jan. 28.

ASML Holding NV starts the week with an upgraded price target, as Morgan Stanley raised its estimate to €1,400 and maintained its stance on the Dutch chip-equipment firm as a top pick.

This call is crucial since ASML occupies a key bottleneck in the chip supply chain. When major chipmakers start opening their wallets, ASML’s bookings and order chatter usually lead the way. Traders are now scrambling to gauge the shape of the upcoming spending cycle.

Morgan Stanley’s Lee Simpson bumped his price target to €1,400 from €1,000 and kept an Overweight rating, signaling confidence the stock will outperform. He pointed to “higher 2027 foundry and memory capex” along with “better than feared China demand.” Simpson projects fiscal 2027 sales around €46.8 billion and earnings per share near €45.7. He also highlighted potential for 80 EUV tools in 2027. EUV, or extreme ultraviolet, refers to the precise lithography equipment essential for cutting-edge chip production. Investing.com

ASML closed Friday in Amsterdam at 1,167.20 euros, gaining 17.80 euros, after fluctuating between 1,150 and 1,183.80 euros during the session. U.S. trading for the stock will be halted Monday as U.S. markets observe Martin Luther King Jr. Day.

Investors are less focused on the target number itself and more on whether orders begin to stack up behind it. The key metric is order intake — the value of new orders secured — which can shift a 2027 projection into something reflected in 2026 guidance.

There’s a catch. The bullish outlook depends on chipmakers sticking to their factory spending plans and demand from China remaining strong. Any slowdown in the flow of shippable tools or tighter restrictions on sales could quickly cause trouble.

Export controls continue to be a sticking point. CEO Christophe Fouquet warned that in 2024, U.S. pressure to tighten restrictions on exports to China is likely to persist, no matter who wins the U.S. election.

ASML is gearing up to reset expectations soon. The company plans to release its Q4 and full-year results on Wednesday, Jan. 28. The press release drops at 07:00 CET, with a press conference scheduled for 11:00 CET, followed by an investor call at 15:00 CET featuring CEO Fouquet and CFO Roger Dassen.

Investors are also tuned in for any news on capital returns. ASML revealed alongside its third-quarter 2025 results that it plans to roll out a new share buyback program in January 2026.

Looking ahead, the next key events are Monday’s reopening in Amsterdam, followed by the Jan. 28 earnings report. Traders will be watching closely for bookings, updated guidance, and any evidence that the 2027 spending projections are shifting from analyst forecasts to real orders.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
3i Group share price: Action’s France sales signal and the Jan. 29 update traders are watching
Previous Story

3i Group share price: Action’s France sales signal and the Jan. 29 update traders are watching

Glencore share price rises as China scrutiny hangs over Rio Tinto merger talks
Next Story

Glencore share price rises as China scrutiny hangs over Rio Tinto merger talks

Go toTop